Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival

PURPOSE: Iodine-125 ((125)I) brachytherapy (BT) alone for intermediate-risk (IR) prostate adenocarcinoma (PCA) is controversial. The purpose of the study was to investigate potential predictive factors in selected IR-PCA patients treated with BT. MATERIAL AND METHODS: Among 547 patients treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Robin, Sophie, Chabaud, Sylvie, Serre, Anne-Agathe, Bringeon, Béatrice, Clippe, Sébastien, Rocher, François, Desmettre, Olivier, Bringeon, Gabriel, Gassa, Frédéric, Pommier, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407263/
https://www.ncbi.nlm.nih.gov/pubmed/34484351
http://dx.doi.org/10.5114/jcb.2021.108592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407263/
https://www.ncbi.nlm.nih.gov/pubmed/34484351
http://dx.doi.org/10.5114/jcb.2021.108592

Ejemplares similares